Combination of anticoagulant and antiaggregant treatment in patients after myocardial infarction with an indication for anticoagulant treatment – so‑ called triple therapy

Česká verzia

Authors: R. Lábrová
Authors place of work: Interní kardiologická klinika LF MU a FN Brno
Published in the journal: Kardiol Rev Int Med 2014, 16(6): 464-471
Category: Cardiology Review

Summary

Anticoagulant therapy is indicated in patients with artificial heart valves, in most patients with atrial fibrillation and in thromboembolic diseases to reduce embolisms. Dual antiaggregant treatment fails in these indications. Patients who have suffered from acute coronary syndrome have a higher risk of cardiovascular complications. If these patients undergo percutaneous coronary intervention with stent implantation, dual antiaggregation is indicated in order to reduce the risk of ischemic attacks, most often with acetylsalycic acid and clopidogrel or newer irreversible blockers of adenosine diphosphate receptors – ticagrelol or prasugrel. However, the combination of both kinds of treatment – anticoagulation and dual antiaggregation, known as triple therapy – increases the risk of bleeding. The ideal therapy for patients with an indication for chronic anticoagulant therapy and receiving percutaneous intervention treatment that would stop thrombotic complications without a higher risk of bleeding is still being sought. The first prospective randomized study, WOEST, showed that warfarin and clopidogrel without acetylsalycic acid is no worse than triple therapy in prevention of thromboembolic complications, and significantly reduces the risk of bleeding. However, this study has not answered the question regarding the administration of ticagrelol or prasugrel. Another question is the administration of the new oral anticoagulants replacing warfarin in indicated cases, in combination with dual antiaggregation.

Key words:
oral anticoagulants – antiplatelet therapy – triple therapy – acute coronary syndrome – percutaneous coronary intervention

Zdroje

1. Lopes RD, Pieper KS, Horton JR et al. Short‑ and long‑term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST‑segment elevation. Heart 2008; 94: 867– 873. doi: 10.1136/ hrt.2007.134486.

2. Camm AJ, Lip GY, De Caterina R et al. ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fi brillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719– 2747. doi: 10.1093/ eurheartj/ ehs253. Epub 2012 Aug 24. Erratum in: Eur Heart J 2013; 34: 790. Eur Heart J 2013; 34: 2850‑ 2851.

3. Lip GY, Lane DA. Does warfarin for stroke thrombopro‑phylaxis protect against MI in atrial fibrillation patients? Am J Med 2010; 123: 785– 789. doi: 10.1016/ j.amjmed.2010.01.031.

4. Heidbuchel H, Verhamme P, Alings M et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non‑valvular atrial fibrillation. Europace 2013; 15: 625– 651. doi: 10.1093/ europace/ eut083.

5. Lip GY, Windecker S, Huber K et al. Management of antitrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/ or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), european Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia‑ Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014; 35: 3155– 3179. doi: 10.1093/ eurheartj/ ehu298.

6. Connoly S, Poque J, Hart R et al. ACTIVE investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrilation in the ACTIVE W: a randomised controlled trial. Lancet 2006; 367: 1903– 1912.

7. Hurlen M, Abdelnoor M, Smith P et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347: 969– 974.

8. Rothberg MB, Celestin C, Fiore LD et al. Warfarin plus aspirin after myocardila infarction or the acute coronary syndrome: meta‑analysis with estimates or risk and benefit. Ann Intern Med 2005; 143: 241– 250.

9. Andreotti F, Testa L, Biondi‑ Zoccai GG et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta‑analysis of 25,307 patients. Eur Heart J 2006; 27: 519– 526.

10. Dewilde WJ, Oirbans T, Verheugt FW et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open‑ label, randomised, controlled trial. Lancet 2013; 381: 1107– 1115. doi: 10.1016/ SO140‑ 6736 (12) 62177‑ 1.

11. Sorensen R, Hansen ML, Abildstrom SZ et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: retrospective analysis of nationwide registry data. Lancet 2009; 374: 1967– 1974. doi: 10.1016/ S0140‑ 6736(09)61751‑ 7.

12. Hohnloser SH, Oldgren J, Yang S et al. Myocardial ischemic events in patients with atrila fibrillation treated with dabigatran or warfarin in the RE‑ LY (Randomized Evaluation of Long‑Term Anticoagulation Therapy) trial. Circulation 2012; 125: 669– 676. doi: 10.1161/ CIRCULATIONAHA.111.055970.

13. Ruff CT, Giugliano RP, Braunwald E et al. Comparison of the efficacy and safety of new oral anticoagulans with warfarin in patients with atrial fibrillation: a meta‑analysis of randomised trials. Lancet 2014; 383: 955– 962. doi: 10.1016/ S0140‑ 6736(13)62343‑ 0.

14. Mark KH. Coronary and mortality risk of novel oral antithrombotic agents: a meta‑analysis of large randomized trials. BMJ Open 2012; 2: e001592. doi: 10.1136/ bmjopen‑ 2012‑ 001592.

15. Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9– 19. doi: 10.1056/ NEJMoa1112277.

16. Karjalainen PP, Vikman S, Niemela M et al. Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment. Eur Heart J 2008; 29: 1001– 1010. 10.1093/ eurheartj/ ehn099.

17. Mehta SR, Granger CB, Eikelboom JW et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS‑ 5 trial. J Am Coll Cardiol 2007; 50: 1742– 1751.

18. Kirchhof P, Breithardt G, Aliot E et al. Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence. NETwork/ European Heart Rhythm Association consensus conference. Europace 2013; 15: 1540– 1556. doi: 10.1093/ europace/ eut232.

19. Oldgren J, Budaj A, Granger CB et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double‑blind, phase II trial. Eur Heart J 2011; 32: 2781– 2789. doi: 10.1093/ eurheartj/ ehr113.

20. Mega JL, Braunwald E, Mohanavelu S et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS‑ TIMI 46): a randomised, double‑blind phase II trial. Lancet 2009; 374: 29– 38. doi: 10.1016/ S0140‑ 6736(09)60738‑ 8.

21. Alexander JH, Lopes RD, James S et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365: 699– 708. doi: 10.1056/ NEJMoa1105819.

22. De Caterina R, Husted S, Wallentin L et al. Vitamin K antagonists in heart disease: Current status and perspectives (Section III). Position Paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087– 1107. doi: 10.1160/ TH13‑ 06‑ 0443.

23. Apostolakis S, Sullivan RM, Olshansky B et al. Factors affecting quality of anticoagulantion control among patients with atrial fibrillation on warfarin: the SAMe‑ TT2R2 Score. Chest 2013; 144: 1555– 1563. doi: 10.1378/ chest.13‑ 0054.

24. Poli D, Antonucci E, Testa S et al. A procpective validation of the SAME‑ TT2R2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. Intern Emerg Med 2014; 9: 443– 447. doi: 10.1007/ s11739‑ 014‑ 1065‑ 8.

25. Lopes RD, Elliott LE, White HD et al. Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX‑ AMI trial. Eur Heart J 2009; 30: 2019– 2028. doi: 10.1093/ eurheartj/ ehp213.

26. Oldgren J, Wallentin L, Alexander JH et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after acute coronary syndrome: a systematic review and meta‑analysis. Eur Heart J 2013; 34: 1670– 1680. doi: 10.1093/ eurheartj/ eht049.

27. Lamberts M, Olesen JB, Ruwald MH et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation 2012; 126: 1185– 1193. doi: 10.1161/ CIRCULATIONAHA.112.114967.